NCT05266430View on ClinicalTrials.gov

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

TerminatedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

April 20, 2023

Conditions
Choroidal MelanomaIndeterminate Lesions
Interventions
OTHER

Standard of Care

Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator

DRUG

AU-011

Previously received

Trial Locations (7)

29605

Retina Consultants of Carolina, PA, Greenville

37203

St. Thomas Health/Tennessee Retina, P.C., Nashville

48073

Associated Retinal Consultants, P.C., Royal Oak

53705

University of Wisconsin Dept of Ophthalmology & Visual Sciences, Madison

75231

Texas Retina Associates, Dallas

77401

Retina Consultants of Texas, Bellaire

97239

Oregon Health & Science University Casey Eye Institute, Portland

Sponsors

Lead Sponsor

Aura Biosciences
All Listed Sponsors
lead

Aura Biosciences

INDUSTRY

NCT05266430 - Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) | Biotech Hunter | Biotech Hunter